Revolution Medicines (RVMD) Peer Comparison
$190.83
$2.11
(1.12%)
As on 29-Oct-2026 10:38EDT
Market cap
$40,079 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
16.1
Div. Yield
0 %
Edit
| Revolution Medicines (RVMD) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | Regeneron Pharmaceuticals (REGN) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
40,079 | 132,796 | 79,887 | 82,881 | 45,811 |
Revenue ($ Mln) |
-- | 12,624 | 2,228 | 15,535 | 16,983 |
Net Profit ($ Mln) |
-1,768.29 | 4,405.20 | -3,151.00 | 4,328.70 | 1,375.00 |
Net Margin (%) |
-- | 34.89 | -141.43 | 27.86 | 8.10 |
RoE (%) |
-83.46 | 22.64 | -40.89 | 13.75 | 21.63 |
Price to Earnings |
-- | 29.90 | -- | 19.91 | 34.57 |
Price-To-Book |
16.11 | 6.46 | 9.33 | 2.54 | 7.14 |
Income Statement ($ Mln)
| Revolution Medicines (RVMD) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | Regeneron Pharmaceuticals (REGN) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 12,624.30 | 2,228.00 | 15,534.70 | 16,983.00 |
|
Cost of Revenue
|
9.24 | 1,762.80 | 2,508.00 | 2,352.10 | 12,528.00 |
|
Gross Profit
|
-16.56 | 10,267.50 | 1,076.00 | 12,242.20 | 5,430.00 |
|
Operating Expenses
|
1,618.01 | 5,989.90 | 3,040.00 | 9,212.50 | 2,150.00 |
|
Operating Profit (EBIT)
|
-1,627.25 | 4,872.00 | -3,320.00 | 3,970.10 | 2,305.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-1,768.29 | 5,274.90 | -3,087.00 | 5,166.00 | 1,609.00 |
|
Provision for Tax
|
0.00 | 869.30 | 64.00 | 837.30 | 253.00 |
|
Profit after Tax (Net Income)
|
-1,768.29 | 4,405.20 | -3,151.00 | 4,328.70 | 1,375.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | -4.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 845.00 |
Liabilities ($ Mln)
| Revolution Medicines (RVMD) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | Regeneron Pharmaceuticals (REGN) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,606.24 | 20,247.90 | 6,761.00 | 31,711.00 | 6,171.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | -4.00 |
|
Non-Current Liabilities
|
1,362.97 | 3,237.50 | 1,666.00 | 4,488.60 | 14,765.00 |
|
Current Liabilities
|
354.06 | 3,937.90 | 2,534.00 | 5,530.60 | 8,815.00 |
|
Total Liabilities
|
2,354.51 | 26,142.80 | 12,338.00 | 40,558.70 | 29,944.00 |
Assets ($ Mln)
| Revolution Medicines (RVMD) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | Regeneron Pharmaceuticals (REGN) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
294.93 | 14,879.60 | 5,146.00 | 23,284.00 | 23,655.00 |
|
Current Assets
|
4,028.34 | 12,543.70 | 5,815.00 | 18,446.00 | 6,226.00 |
|
Total Assets
|
2,354.51 | 26,142.80 | 12,338.00 | 40,558.70 | 29,944.00 |
|
Total Debt*
|
641.93 | 1,977.60 | 1,287.00 | 1,986.60 | 16,241.00 |
|
Net Current Assets
|
3,674.28 | 8,605.80 | 3,281.00 | 12,915.40 | -2,589.00 |
Cashflow ($ Mln)
| Revolution Medicines (RVMD) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | Regeneron Pharmaceuticals (REGN) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-897.74 | 3,631.40 | -1,873.00 | 4,978.90 | 2,654.00 |
|
Cash Flow from Investing Activities
|
118.06 | -945.40 | 1,946.00 | -629.10 | -2,305.00 |
|
Cash from Financing Activities
|
621.52 | -2,261.30 | 593.00 | -3,715.40 | -150.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Revolution Medicines (RVMD) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | Regeneron Pharmaceuticals (REGN) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-53.99 | 19.42 | -25.41 | 13.65 | 6.34 |
|
ROE (%)
|
-83.46 | 22.64 | -40.89 | 13.75 | 21.63 |
|
ROA (%)
|
-48.50 | 14.80 | -23.27 | 9.71 | 3.67 |
|
EBIT Margin (%)
|
-- | 41.84 | -137.79 | 33.61 | 13.81 |
|
Net Margin (%)
|
-- | 34.89 | -141.43 | 27.86 | 8.10 |
|
Cash Profit Margin (%)
|
-- | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Revolution Medicines (RVMD) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | Regeneron Pharmaceuticals (REGN) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 10.56 | -27.19 | 9.29 | 8.17 |
|
EBIT Growth (%)
|
-110.25 | 20.32 | -4.74 | 6.31 | 5.30 |
|
Net Profit Growth (%)
|
-117.75 | 21.10 | -8.54 | -2.91 | 11.16 |
|
EPS Growth (%)
|
-95.21 | 22.80 | -6.34 | 1.72 | 16.60 |
|
Book Value Growth (%)
|
24.65 | 19.36 | -29.52 | 7.70 | 9.72 |
Valuation Ratios
| Revolution Medicines (RVMD) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | Regeneron Pharmaceuticals (REGN) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-13.39 | 29.37 | -4.10 | 18.42 | 28.49 |
|
Price / Book Value
|
9.28 | 6.22 | 1.34 | 2.65 | 5.96 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-12.17 | 23.30 | -3.01 | 13.25 | 17.96 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Revolution Medicines (RVMD) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | Regeneron Pharmaceuticals (REGN) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.19 | 0.00 | 0.09 | 0.06 | 2.22 |
|
Short term debt to equity ratio
|
0.01 | 0.00 | 0.01 | 0.00 | 0.37 |
|
Current Ratio
|
11.38 | 3.19 | 2.29 | 3.34 | 0.71 |
|
Quick Ratio
|
11.38 | 2.74 | 2.18 | 2.78 | 0.71 |
|
Interest Coverage
|
-28.80 | 800.23 | -72.50 | 94.25 | 3.09 |
Operating Efficiency Ratios
| Revolution Medicines (RVMD) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | Regeneron Pharmaceuticals (REGN) | IQVIA Holdings (IQV) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 16.91 | 4.62 | 42.26 | 19.94 |
|
Asset Turnover
|
0.00 | 0.42 | 0.16 | 0.35 | 0.45 |
|
Receivable days
|
-- | 55.39 | 82.29 | 152.19 | 74.65 |
|
Inventory Days
|
-- | 292.28 | 56.81 | 546.66 | -- |
|
Payable days
|
1,312.97 | 88.40 | 151.91 | 150.27 | 75.32 |
|
Cash Conversion Cycle
|
-- | 259.28 | -12.81 | 548.59 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
